Deoxycytidine Kinase (dCK) has been implicated in cancer cell proliferation. Our dCK inhibitor, TRE-515, has been chemically engineered to improve bioavailability and demonstrates robust anti-tumor activity.
TRE-515, a first-in-class inhibitor for treatment of cancer
TRE-515 is a potent and orally-bioavailable inhibitor of dCK that may have monotherapy activity against solid tumors where low expression of the de novo pathway or other metabolic changes occur creating greater sensitivity to nucleotide salvage pathway inhibition.
TRE-515 may also work in combination with de novo nucleotide pathway inhibitors, where both pathways are pharmacologically downregulated.
A novel attack on cancer
Human cell nucleotide synthesis occurs via either the salvage pathway (regulated by deoxycytidine kinase, dCK) or the de novo pathway (regulated ribonucleotide reductase, RNR). Unfortunately, cancer treatments today focus on blocking the de novo pathway, leading to drug resistance. Trethera is developing a platform of drugs attacking different points in cell nucleotide metabolism.